AUTHORS
Leticia Campoverde, MD, Elizabeth Corley, MD2, Guillermo Garcia-Manero, MD3, Farhad Ravandi, MD4, Gautam Borthakur, MD5, Guillermo Montalban-Bravo, MD6, Naval Daver, MD7, Courtney DiNardo, MD, MSCE8, Tapan Kadia I, MD9, Ian Bouligny, M.D.10, Fadi G. Haddad, MD11, Mahesh Swaminathan, MD12, Danielle Hammond, MD13, Steven Kornblau, MD14, Emily Burton15, Samantha MacFadden16, Sasha Johnson17, Regina Abramova18, David Philpot19, Hussein Ali Abbas, MD, PhD20, Aaron D Goldberg, MD, PhD21, Nicholas Short, MD22
AFFILIATIONS
1 MD Anderson Cancer Center Houston, Houston, United States
2 Memorial Sloan Kettering Cancer Center, New York, United States
3 MD Anderson Cancer Center, Houston, United States
4 MD Anderson Cancer Center, Houston, United States
5 MD Anderson Cancer Center, Houston, United States
6 MD Anderson Cancer Center, Houston, United States
7 MD Anderson Cancer Center, Houston, United States
8 MD Anderson Cancer Center, Houston, United States
9 MD Anderson Cancer Center, Houston, United States
10 MD Anderson Cancer Center, Houston, United States
11 MD Anderson Cancer Center, Houston, United States
12 MD Anderson Cancer Center, Houston, United States
13 MD Anderson Cancer Center, Houston, United States
14 MD Anderson Cancer Center, Houston, United States
15 Memorial Sloan Kettering Cancer Center, New York, United States
16 Memorial Sloan Kettering Cancer Center, New York, United States
17 Memorial Sloan Kettering Cancer Center, New York, United States
18 MD Anderson Cancer Center, Houston, United States
19 MD Anderson Cancer Center, Houston, United States
20 MD Anderson Cancer Center, Houston, United States
21 Memorial Sloan Kettering Cancer Center, New York, United States
22 MD Anderson Cancer Center, Houston, United States
ABSTRACT
Background: Preclinical studies suggest that cytokine-mediated activation of the JAK/STAT pathway contributes to resistance to FLT3 inhibitors for acute myeloid leukemia (AML). Emerging evidence also supports a role for ACVR1 signaling in adaptive resistance in FLT3-mutated AML. Momelotinib is an oral inhibitor of JAK1/2 and ACVR1 that also demonstrates possible FLT3 inhibitory activity in preclinical models.
Methods: This single-arm, multicenter, open-label, phase I study enrolled adults with relapsed/refractory (R/R) FLT3-mutated AML, including FLT3-ITD or FLT3-TKD (D835/836). Cycle 1 comprised a 7-day momelotinib monotherapy lead-in (200mg, 400mg, or 600mg once daily), followed by combination therapy with gilteritinib 120mg once daily on days 8-35. Beginning in cycle 2, patients (pts) received continuous momelotinib and gilteritinib given in 28-day cycles. The primary endpoint of the study was the optimal dose of momelotinib in combination with gilteritinib.
Results: Between June 2024 and July 2026, 20 pts were treated. Median age was 67 years (range, 31–84). 17 (85%) had FLT3-ITD and 3 (15%) had FLT3-TKD, with a median FLT3 VAF of 18% (range, 3–59%). Pts had received a median of 3 prior therapies (range, 1–6). Eighteen (90%) had received prior gilteritinib, including 9 (45%) also with prior quizartinib. The most common co-mutations were DNMT3A (45%), RUNX1 (35%), and WT1 (35%). Four pts (20%) had ≥1 RAS/MAPK pathway mutation, and 9 (45%) had adverse-risk cytogenetics.
Thirteen pts were treated during the dose escalation part of the study, which was followed by a dose expansion phase (n=7) at the 400mg and 600mg dose levels. 3 pts received momelotinib 200 mg, 6 received 400 mg, and 11 received 600 mg. No DLTs were observed in the dose escalation phase of the study. The most common grade ≥3 nonhematologic AEs were febrile neutropenia (45%), sepsis (45%), pneumonia (30%), acute kidney injury (25%), and hypotension (20%). One pt experienced a treatment-related grade ≥3 nonhematologic AE: grade 3 hypotension attributed to momelotinib at the 400mg dose. Momelotinib-related hypotension occurred in 5 pts (25%): grade 1 in 2 pts (both 200mg), grade 2 in 2 pts (both 600mg), and grade 3 in 1 pt (400mg). Momelotinib-related dizziness occurred in 3 pts (15%): grade 1 in 2 pts (both 600mg) and grade 2 in 1 pt (400 mg). Two pts (10%) experienced grade 5 nonhematologic AEs (pneumonia and multi-organ failure), both unrelated, in the setting of refractory AML.
Pts received a median of 1 cycle (range, 1–5): 11 pts (55%) received 1 cycle, 6 (30%) received 2, 1 (5%) received 3, and 2 (10%) received 5 cycles. At last follow-up, 2 pts (10%) are still receiving protocol therapy.The CRc rate was 25% (5/20), including CRi in 3 pts (15%) and MLFS in 2 pts (10%). All responses occurred in pts with FLT3-ITD AML at the 400mg or 600mg doses. The CRc rates at the 400mg and 600mg doses were 33% (2/6) and 27% (3/11), respectively. Among the 5 responders, 4 had received prior gilteritinib, including 3 with prior quizartinib. 4 responses were observed after cycle 1 and 1 response was after cycle 2. Two additional pts—one each with FLT3-ITD and FLT3-TKD and both with prior gilteritinib exposure—achieved ≥50% reduction in bone marrow blasts (49% to 6% and 82% to 10%, respectively) not meeting formal response criteria. During the 7-day single-agent momelotinib lead-in, 6/15 evaluable pts (40%) achieved a ≥50% reduction in peripheral blood (PB) blasts, including 2 (13%) with complete PB clearance, supporting the independent biologic activity of momelotinib in this population.
With a median follow-up of 9.1 months (range, 0.8-11.7), 1 responder relapsed (after 2.1 months of remission), 2 died in remission (both due to infection), and 2 remain alive in remission.
Conclusion: The combination of gilteritinib and momelotinib was safe and demonstrated antileukemic activity in a heavily pretreated population with R/R FLT3-mutated AML, including pts previously exposed to gilteritinib, highlighting the potential contribution of momelotinib to the responses observed. Both 400mg and 600mg doses of momelotinib were active in combination with gilteritinib. Correlative studies integrating cytokine profiling and single-cell signaling analyses are ongoing to characterize JAK/STAT and ACVR1/SMAD pathway modulation and identify mechanisms of response and resistance. This study has been amended to add venetoclax to this combination and is expanding to additional sites.
DISCLOSURES
Leticia Campoverde, MD: No relevant conflicts of interest to declare.